Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 5/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.47 |
| ▸ | MMP13 | P45452 | 3/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP14 | P50281 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP10 | P09238 | 1/20 | 0.43 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19544482 | 0.80 | FFAR1 (0.50) | MMP12FFAR1NPC1NFKB1RAB9A | |
| SCHEMBL19544342 | 0.76 | FFAR1 (0.54) | MMP12FFAR1NPC1NFKB1RAB9A | |
| SCHEMBL7796725 | 0.71 | FFAR1 (0.54) | FFAR1NPC1RAB9ASMN1; SMN2FFAR4 | |
| SCHEMBL10008805 | 0.69 | ADORA3 (0.59) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL22449177 | 0.69 | NR1H4 (0.49) | NPC1RAB9ASMN1; SMN2PRCP | |
| SCHEMBL22361824 | 0.69 | MAPT (0.56) | FFAR1MMEHDAC2 | |
| SCHEMBL19418905 | 0.69 | MAPT (0.56) | FFAR1MMEHDAC2 | |
| SCHEMBL16375212 | 0.68 | PTPN1 (0.57) | MMEACE | |
| SCHEMBL22449131 | 0.68 | RXRA (0.62) | FFAR1 | |
| SCHEMBL7796867 | 0.68 | RARB (0.61) | FFAR1NPC1NFKB1RAB9ANFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | MMP12 4516/4885MMP2 3978/4885MMP13 4488/4885 |
| US-10259823-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | MMP12 4447/4885MMP2 3977/4885MMP13 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.